P1060

Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV-Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-to-Child HIV Transmission

Sponsors: US National Institute of Allergy and Infectious Diseases (NIAD)
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Protocol Summary: P1060 is designed to compare the effectiveness of a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral regimen versus a protease inhibitor (PI)-based regimen in HIV infected infants who had or had not been exposed to single dose Nevirapine for prevention of MTCT.

Years: 2007 – 2012

Investigator: Mutsawashe Bwakura-Dangarembizi, MBChB, MMED, MSc Cli.Epi

Location: Parirenyatwa CRS

IMPAACT

Completed Study

Publication:

Violari A, Lindsey JC, Hughes MD, Mujuro HA, Barlow-Mosha L, et al. (2012) Nevirapine versus rtonavir-boosted lopinavir for HIV-infected children. N Engl J Med; 366 (25): 2380-9.

Lindsey JC, Hughes MD, Violari A. et al (2014) Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Pediatr Infect Dis J. 2014 Aug;33(8):846-54.